LRRK2 and Parkinson disease: The immunostaining of LRRK2+ cells and western blot analysis in striatum showed that LRRK2 was upregulated in vehicle-treated PD models compared to normal controls, but was inhibited by treatment with C16, Ang-1, and the combination of C16 and Ang-1 (Supplementary Fig. 2).